HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Joanne Halsey Selected Research

ISIS 3521

10/2005A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Joanne Halsey Research Topics

Disease

3Neoplasms (Cancer)
03/2006 - 01/2004
2Adenocarcinoma
11/2008 - 08/2005
2Colorectal Neoplasms (Colorectal Cancer)
11/2008 - 08/2005
1Exanthema (Rash)
11/2008
1Diarrhea
03/2006
1Carcinoma (Carcinomatosis)
01/2004

Drug/Important Bio-Agent (IBA)

3Oxaliplatin (Eloxatin)FDA LinkGeneric
11/2008 - 08/2005
3Gefitinib (Iressa)FDA Link
11/2008 - 08/2005
3Leucovorin (Folinic Acid)FDA Link
11/2008 - 08/2005
3Fluorouracil (Carac)FDA LinkGeneric
11/2008 - 08/2005
2Protein Kinase C-alphaIBA
10/2005 - 01/2004
2aprinocarsenIBA
10/2005 - 01/2004
2Antisense OligonucleotidesIBA
10/2005 - 01/2004
1AntidiarrhealsIBA
03/2006
1ISIS 3521IBA
10/2005
1Proteins (Proteins, Gene)FDA Link
01/2004

Therapy/Procedure

2Drug Therapy (Chemotherapy)
11/2008 - 08/2005
2Therapeutics
11/2008 - 08/2005
1Intravenous Infusions
01/2004